NASDAQ:INO - Inovio Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $12.00
  • Forecasted Upside: 14.39 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$10.49
▼ -0.43 (-3.94%)
1 month | 3 months | 12 months
Get New Inovio Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.00
▲ +14.39% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Inovio Pharmaceuticals in the last 3 months. The average price target is $12.00, with a high forecast of $20.00 and a low forecast of $7.00. The average price target represents a 14.39% upside from the last price of $10.49.
Hold
The current consensus among 9 investment analysts is to hold stock in Inovio Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/8/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/6/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/4/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
2/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
9/29/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
10/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/28/2020Roth CapitalLower Price Target$11.00 ➝ $8.00High
i
Rating by J. Aschoff at Roth Capital
9/28/2020Maxim GroupUpgradeHold ➝ Buy$20.00High
i
Rating by Naureen Quibria at Maxim Group
9/28/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$31.00 ➝ $12.00High
i
Rating by C. Duncan at Cantor Fitzgerald
9/9/2020HC WainwrightReiterated RatingHoldHigh
i
Rating by R. Selvaraju at HC Wainwright
8/11/2020Stifel NicolausLower Price Target$24.00 ➝ $16.00Medium
i
Rating by Stephen Willey at Stifel Nicolaus
8/11/2020Cantor FitzgeraldLower Price Target$45.00 ➝ $31.00Medium
i
7/1/2020Roth CapitalDowngradeNeutral ➝ Sell$11.00High
i
Rating by J. Aschoff at Roth Capital
7/1/2020Maxim GroupDowngradeBuy ➝ Hold$24.00High
i
Rating by Jason McCarthy at Maxim Group
6/30/2020BenchmarkReiterated RatingBuyHigh
i
Rating by Aydin Huseynov at Benchmark Co.
6/29/2020HC WainwrightDowngradeBuy ➝ NeutralMedium
i
Rating by Ram Selvaraju at HC Wainwright
6/26/2020Stifel NicolausDowngradeBuy ➝ Hold$19.00 ➝ $24.00High
i
Rating by Stephen Willey at Stifel Nicolaus
6/23/2020Maxim GroupBoost Price Target$18.00 ➝ $24.00High
i
Rating by Jason McCarthy at Maxim Group
6/5/2020HC WainwrightReiterated RatingBuy$17.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/21/2020HC WainwrightReiterated RatingBuy$17.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/21/2020BenchmarkInitiated CoverageBuyHigh
i
5/13/2020Maxim GroupReiterated RatingBuy$18.00High
i
Rating by Jason McCarthy at Maxim Group
5/12/2020HC WainwrightReiterated RatingBuy$17.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/30/2020Roth CapitalDowngradeBuy ➝ Neutral$13.00High
i
Rating by J. Aschoff at Roth Capital
4/29/2020Stifel NicolausBoost Price TargetBuy$8.00 ➝ $19.00Medium
i
Rating by Stephen Willey at Stifel Nicolaus
4/29/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$13.00 ➝ $17.00High
i
4/28/2020HC WainwrightReiterated RatingBuy$13.00 ➝ $17.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
4/17/2020HC WainwrightReiterated RatingBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/15/2020Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $13.00Medium
i
4/7/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by Ram Selvaraju at HC Wainwright
4/6/2020Royal Bank of CanadaDowngradeHoldHigh
i
Rating by Gregory Renza at Royal Bank of Canada
3/27/2020Maxim GroupInitiated CoverageBuy$12.00High
i
Rating by Jason McCarthy at Maxim Group
3/13/2020Maxim GroupBoost Price TargetBuy$6.00 ➝ $12.00Low
i
Rating by Jason McCarthy at Maxim Group
3/13/2020Piper SandlerDowngradeOverweight ➝ Neutral$8.00High
i
3/13/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$7.00Low
i
Rating by Gregory Renza at Royal Bank of Canada
3/4/2020Stifel NicolausReiterated RatingBuy$7.00High
i
Rating by Stephen Willey at Stifel Nicolaus
3/3/2020HC WainwrightReiterated RatingBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/11/2020HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
2/4/2020HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/24/2020HC WainwrightReiterated RatingBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/23/2020Maxim GroupReiterated RatingBuyHigh
i
Rating by Jason McCarthy at Maxim Group
1/23/2020Royal Bank of CanadaReiterated RatingBuy$7.00High
i
Rating by Gregory Renza at Royal Bank of Canada
1/6/2020Cantor FitzgeraldReiterated RatingOverweightN/A
i
1/3/2020HC WainwrightReiterated RatingBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/2/2020Piper Jaffray CompaniesLower Price TargetOverweight$10.00 ➝ $8.00High
i
12/19/2019Roth CapitalInitiated CoverageBuy$13.00High
i
Rating by J. Aschoff at Roth Capital
11/14/2019Maxim GroupReiterated RatingBuyHigh
i
Rating by Jason McCarthy at Maxim Group
11/13/2019HC WainwrightReiterated RatingBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
9/18/2019HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/16/2019CitigroupReiterated RatingBuy$7.00 ➝ $4.00Medium
i
8/11/2019Maxim GroupReiterated RatingBuy$6.00High
i
Rating by Jason McCarthy at Maxim Group
7/17/2019Piper Jaffray CompaniesLower Price TargetOverweight$12.00 ➝ $10.00High
i
6/11/2019HC WainwrightReiterated RatingBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/16/2019HC WainwrightInitiated CoverageBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/7/2019HC WainwrightReiterated RatingBuyHigh
i
Rating by Ram Selvaraju at HC Wainwright
4/22/2019HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
4/3/2019Maxim GroupReiterated RatingBuy$8.00Medium
i
Rating by Jason McCarthy at Maxim Group
4/2/2019HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/25/2019Cantor FitzgeraldInitiated CoverageOverweight$12.00 ➝ $3.62Medium
i
Rating by C. Duncan at Cantor Fitzgerald
3/22/2019HC WainwrightReiterated RatingBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
3/5/2019HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/20/2019Maxim GroupSet Price TargetBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
1/25/2019HC WainwrightReiterated RatingBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/16/2019HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/15/2019Maxim GroupReiterated RatingBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
12/5/2018HC WainwrightInitiated CoverageBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/27/2018HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/26/2018Maxim GroupSet Price TargetBuy$8.00Medium
i
Rating by Jason McCarthy at Maxim Group
11/12/2018HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
10/23/2018HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/16/2018HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
10/9/2018HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/2/2018Stifel NicolausInitiated CoverageBuy ➝ Buy$8.00High
i
9/18/2018HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/16/2018Maxim GroupReiterated RatingBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
8/15/2018HC WainwrightSet Price TargetBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/7/2018HC WainwrightSet Price TargetBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/21/2018Maxim GroupReiterated RatingBuy$8.00Medium
i
Rating by Jason McCarthy at Maxim Group
5/16/2018HC WainwrightSet Price TargetBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/10/2018HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/10/2018Maxim GroupSet Price TargetBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
4/12/2018HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/11/2018Maxim GroupSet Price TargetBuy$8.00Medium
i
Rating by Jason McCarthy at Maxim Group
3/21/2018HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
3/15/2018Royal Bank of CanadaBoost Price TargetOutperform$11.00 ➝ $14.00High
i
3/15/2018HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/15/2018Maxim GroupSet Price TargetBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
2/15/2018Maxim GroupLower Price TargetBuy ➝ Buy$12.00 ➝ $8.00Low
i
Rating by Jason McCarthy at Maxim Group
2/13/2018HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/23/2018HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/12/2018HC WainwrightSet Price TargetBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/3/2018HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/2/2018Maxim GroupSet Price TargetBuy$12.00High
i
11/28/2017HC WainwrightSet Price TargetBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/9/2017HC WainwrightReiterated RatingBuy$13.00N/A
i
Rating by R. Selvaraju at HC Wainwright
10/25/2017HC WainwrightSet Price TargetBuy$13.00N/A
i
Rating by R. Selvaraju at HC Wainwright
10/18/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$11.00N/A
i
10/17/2017HC WainwrightSet Price TargetBuy$13.00N/A
i
Rating by R. Selvaraju at HC Wainwright
10/6/2017HC WainwrightSet Price TargetBuy$13.00N/A
i
Rating by R. Selvaraju at HC Wainwright
10/6/2017CitigroupInitiated CoverageBuy$10.00N/A
i
9/22/2017HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by R. Selvaraju at HC Wainwright
9/12/2017HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by R. Selvaraju at HC Wainwright
9/12/2017Maxim GroupReiterated RatingBuy$12.00Low
i
9/6/2017CitigroupInitiated CoverageBuy ➝ Buy$10.00High
i
8/9/2017HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Y. Chen at HC Wainwright
8/9/2017Maxim GroupSet Price TargetBuy$12.00High
i
7/27/2017HC WainwrightSet Price TargetBuy$13.00High
i
Rating by Y. Chen at HC Wainwright
7/18/2017AegisReiterated RatingBuy$14.00Low
i
Rating by J. Wittes at Aegis
7/7/2017HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Y. Chen at HC Wainwright
6/9/2017HC WainwrightReiterated RatingBuy$13.00Low
i
Rating by Y. Chen at HC Wainwright
6/8/2017Maxim GroupSet Price TargetBuy$12.00High
i
6/8/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$14.00Medium
i
6/3/2017HC WainwrightSet Price TargetBuy$13.00Medium
i
Rating by Y. Chen at HC Wainwright
6/1/2017Maxim GroupReiterated RatingBuy$12.00Low
i
5/28/2017HC WainwrightReiterated RatingBuy$13.00High
i
Rating by Y. Chen at HC Wainwright
5/25/2017AegisBoost Price TargetBuy$11.00 ➝ $14.00Low
i
Rating by J. Wittes at Aegis
5/25/2017Stifel NicolausReiterated RatingBuy$11.00High
i
5/24/2017Maxim GroupBoost Price TargetBuy ➝ Buy$10.00 ➝ $12.00High
i
5/17/2017AegisReiterated RatingBuy$11.00Low
i
Rating by J. Wittes at Aegis
5/11/2017HC WainwrightSet Price TargetBuy$13.00Low
i
Rating by Y. Chen at HC Wainwright
5/11/2017Maxim GroupReiterated RatingBuyHigh
i
5/1/2017Nomura SecuritiesReiterated RatingBuy$40.00Low
i
5/1/2017Jefferies Financial GroupReiterated RatingNeutral$38.00Low
i
5/1/2017BNP ParibasReiterated RatingNeutral$39.00Low
i
4/25/2017Stifel NicolausReiterated RatingBuy$11.00High
i
3/21/2017AegisReiterated RatingBuyLow
i
Rating by J. Wittes at Aegis
3/16/2017HC WainwrightSet Price TargetBuy$13.00Medium
i
Rating by Y. Chen at HC Wainwright
3/16/2017Maxim GroupUpgradeHold ➝ Buy$10.00High
i
3/16/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$13.00 ➝ $9.00High
i
2/24/2017HC WainwrightReiterated RatingBuy$13.00N/A
i
Rating by Y. Chen at HC Wainwright
2/23/2017Maxim GroupReiterated RatingHoldN/A
i
12/23/2016Stifel NicolausReiterated RatingBuy$11.00N/A
i
12/23/2016HC WainwrightReiterated RatingBuy$13.00N/A
i
11/11/2016HC WainwrightReiterated RatingBuy$17.00 ➝ $13.00N/A
i
11/7/2016AegisInitiated CoverageBuy$12.00N/A
i
10/26/2016HC WainwrightReiterated RatingBuy$17.00N/A
i
10/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$31.00 ➝ $13.00N/A
i
10/24/2016Stifel NicolausLower Price TargetBuy$11.00N/A
i
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/A
i
8/29/2016HC WainwrightInitiated CoverageBuy$17.00N/A
i
8/18/2016Maxim GroupReiterated RatingHoldN/A
i
8/13/2016HC WainwrightReiterated RatingBuy$17.00N/A
i
8/9/2016Maxim GroupDowngradeBuy ➝ HoldN/A
i
8/8/2016Brean CapitalSet Price TargetBuy$18.00N/A
i
8/8/2016Piper Jaffray CompaniesReiterated RatingOverweight$31.00N/A
i
7/18/2016Piper Jaffray CompaniesReiterated RatingOverweight$31.00N/A
i
7/17/2016Stifel NicolausReiterated RatingBuy$13.00N/A
i
6/21/2016Maxim GroupReiterated RatingBuy$14.00N/A
i
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/A
i
6/21/2016HC WainwrightReiterated RatingBuy$17.00N/A
i
5/25/2016National Bank FinancialDowngradeOutperform Market Weight ➝ Sector Perform Market WeightN/A
i
Rating by M. Kornack at National Bank Financial
5/17/2016Maxim GroupReiterated RatingBuy$14.00N/A
i
5/9/2016Maxim GroupReiterated RatingBuyN/A
i
5/9/2016Stifel NicolausReiterated RatingBuy$13.00N/A
i
4/27/2016Maxim GroupReiterated RatingBuy$14.00N/A
i
4/9/2016Rodman & RenshawReiterated RatingBuyN/A
i
3/28/2016DesjardinsDowngradeBuy ➝ HoldN/A
i
Rating by M. Markidis at Desjardins
3/24/2016Maxim GroupReiterated RatingBuy$14.00N/A
i
3/20/2016Rodman & RenshawReiterated RatingBuyN/A
i
3/20/2016HC WainwrightReiterated RatingBuy$17.00N/A
i
3/15/2016Stifel NicolausReiterated RatingBuy$19.00 ➝ $13.00N/A
i
3/15/2016Maxim GroupReiterated RatingBuy$14.00N/A
i
3/14/2016Brean CapitalLower Price TargetBuy$20.00 ➝ $18.00N/A
i
2/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$31.00N/A
i
2/21/2016HC WainwrightReiterated RatingBuy$17.00N/A
i
2/13/2016Maxim GroupReiterated RatingBuy$14.00N/A
i
2/1/2016HC WainwrightReiterated RatingBuy$17.00N/A
i
1/29/2016Rodman & RenshawReiterated RatingBuyN/A
i
1/20/2016Maxim GroupReiterated RatingBuy$14.00N/A
i
1/5/2016Maxim GroupLower Price TargetBuy$23.00 ➝ $14.00N/A
i
11/11/2015Stifel NicolausReiterated RatingBuy$19.00N/A
i
(Data available from 10/29/2015 forward)
Inovio Pharmaceuticals logo
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $10.49
$10.45
$11.08

50 Day Range

MA: $12.77
$9.61
$18.52

52 Week Range

Now: $10.49
$2.09
$33.79

Volume

5,146,998 shs

Average Volume

28,595,355 shs

Market Capitalization

$1.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02